Research ArticleCORONAVIRUS
Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response
- View ORCID ProfileAshish Goyal1,*,
- View ORCID ProfileE. Fabian Cardozo-Ojeda1,* and
- View ORCID ProfileJoshua T. Schiffer1,2,3,†
- 1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
- 2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
- 3Department of Medicine, University of Washington, Seattle, WA, USA.
- ↵†Corresponding author. Email: jschiffe{at}fredhutch.org
↵* These authors contributed equally to this work.
See allHide authors and affiliations
Science Advances 20 Nov 2020:
Vol. 6, no. 47, eabc7112
DOI: 10.1126/sciadv.abc7112
Vol. 6, no. 47, eabc7112
DOI: 10.1126/sciadv.abc7112
Ashish Goyal
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
E. Fabian Cardozo-Ojeda
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Joshua T. Schiffer
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
3Department of Medicine, University of Washington, Seattle, WA, USA.